Related Experiment Video
Updated: May 19, 2026
08:47
Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
Nicotine vaccines for smoking cessation.
Jamie Hartmann-Boyce1, Kate Cahill, Dorothy Hatsukami
1Department of Primary Care Health Sciences, University ofOxford, Oxford, UK. jamie.hartmann-boyce@phc.ox.ac.uk.
The Cochrane Database of Systematic Reviews
|August 17, 2012
Summary
Nicotine vaccines do not currently show evidence of enhancing long-term smoking cessation. While generally well-tolerated, further trials are needed to confirm their efficacy and safety for smoking cessation and relapse prevention.
Area of Science:
- Pharmacology
- Immunology
- Addiction Medicine
Background:
- Nicotine vaccines aim to reduce nicotine reaching the brain, potentially aiding smoking cessation and relapse prevention.
- Several nicotine vaccine candidates are under development, with some having completed Phase II and III trials.
Purpose of the Study:
- To assess the efficacy of nicotine vaccines for smoking cessation and relapse prevention.
- To evaluate the frequency and types of adverse events associated with nicotine vaccines.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) of nicotine vaccines.
- Inclusion of Phase II and III trials in adult smokers or recent ex-smokers.
- Primary outcome: minimum six months continuous abstinence from smoking, preferably 12-month biochemically validated rates.
Main Results:
- Four RCTs met inclusion criteria; none demonstrated a statistically significant difference in long-term cessation rates compared to placebo.
- Two studies showed higher cessation rates in participants with higher nicotine antibody levels, but this requires further investigation.
- Nicotine vaccines were generally well-tolerated, with most adverse events being mild to moderate; serious adverse events were rare.
Conclusions:
- Current evidence does not support the efficacy of nicotine vaccines for long-term smoking cessation.
- Further rigorous trials are necessary to evaluate nicotine vaccines for smoking cessation and relapse prevention.
- Comprehensive reporting of outcomes and adverse events in future trials is crucial.
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Stimulants
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:15Cholinergic Receptors: Nicotinic
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...